Urinary bladder disorders

Trigone Pharma to Present Preclinical Data for TRG-100 in Interstitial Cystitis / Bladder Pain Syndrome at the Upcoming American Urological Association Conference (AUA) in September 2021

Retrieved on: 
Thursday, July 22, 2021
Medical specialties, Anatomy, Urinary bladder disorders, Urology, Interstitial cystitis, Trigone, Urinary bladder, Overactive bladder, Renal colic

IC/BPS and its associated pain significantly affects quality of life, including loss of work, and is associated with suicidal rates five-to-seven times the national average.

Key Points: 
  • IC/BPS and its associated pain significantly affects quality of life, including loss of work, and is associated with suicidal rates five-to-seven times the national average.
  • Our preliminary results should be further confirmed in the upcoming Phase IIa trial, said Dan Touitou, Chief Executive Officer of Trigone Pharma.
  • The data has also prompted us to evaluate the safety and efficacy in overactive bladder and renal colic patients.
  • Trigone Pharma is aiming to restore the quality of life for patients suffering from bladder diseases that affect populations with unmet medical needs.

BlueWind Medical Reaches 100th Patient for the OASIS Study of the RENOVA™ iStim System

Retrieved on: 
Tuesday, July 6, 2021
Branches of biology, Anatomy, Neurotechnology, Urinary bladder disorders, Overactive bladder, Neuromodulation, OAB, Renova, Implant, Urinary bladder

The Overactive Bladder Stimulation System Study (OASIS) clinical pivotal study is designed to test the safety and efficacy of the RENOVA iStim System in providing tibial neuromodulation (TNM) therapy.

Key Points: 
  • The Overactive Bladder Stimulation System Study (OASIS) clinical pivotal study is designed to test the safety and efficacy of the RENOVA iStim System in providing tibial neuromodulation (TNM) therapy.
  • "I had the privilege of taking part both to the pilot and pivotal trials of the RENOVA iStim System" said Dr. Digesu.
  • "I find the RENOVA iStim a device easy to implant for a surgeon and easy to operate for a patient."
  • BlueWind Medical, founded in 2010, is developing the RENOVA iStim, a miniature, wireless neurostimulator to treat Overactive Bladder (OAB).

2021 Global Overactive Bladder Epidemiology and Patient Flow Report - ResearchAndMarkets.com

Retrieved on: 
Friday, May 14, 2021
Health, General Health, Medical specialties, Branches of biology, Urinary bladder disorders, Clinical medicine, Overactive bladder, Urinary bladder, Urinary incontinence

b'The "Global Overactive Bladder Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis research report provides Overactive Bladder epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Overactive Bladder Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis research report provides Overactive Bladder epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Overactive Bladder patients, history of the disease at the population level (Overactive Bladder prevalence, Overactive Bladder incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Overactive Bladder patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Overactive Bladder market sizing, assessing market potential, and developing drug forecast models\nIdentify Overactive Bladder patients segments through age groups, gender, and disease sub-types\nEvaluate Overactive Bladder market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210514005332/en/\n'

Dovel Subsidiary, Medical Science & Computing, LLC (MSC) Awarded NIH NIDDK IDIQ

Retrieved on: 
Thursday, April 29, 2021
Data management, Health, Diabetes, Technology, Other Health, Managed care, Networks, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Biorepository, Health, Medical specialties, Urinary bladder disorders, Endocrine and Metabolic Diseases Information Service, National Digestive Diseases Information Clearinghouse

b'Dovel Technologies announced today that its subsidiary Medical Science & Computing, LLC (MSC) has been awarded a multi-award Indefinite Delivery Indefinite Quantity (IDIQ) contract from the National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Key Points: 
  • b'Dovel Technologies announced today that its subsidiary Medical Science & Computing, LLC (MSC) has been awarded a multi-award Indefinite Delivery Indefinite Quantity (IDIQ) contract from the National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
  • The work on this contract will focus on expanding the NIDDK Central Repository Program, which is a resource that has potential to advance the development of diagnostic and treatment tools for many diseases.\nThe NIDDK Central Repository Program is made up of two repositories.
  • The NIDDK Biorepository receives bio samples collected from studies, stores the samples, and distributes them to qualified investigators.
  • The NIDDK Data Repository receives, archives, maintains, and distributes data from large clinical studies.

Medtronic Receives FDA Approval to Launch Clinical Study for Implantable Tibial Neuromodulation Therapy for Bladder Incontinence

Retrieved on: 
Tuesday, April 27, 2021
Branches of biology, Neurotechnology, Medical specialties, Neuroscience, Urinary bladder disorders, Neuromodulation, Neurophysiology, Neuropsychology, Sacral nerve stimulation, Overactive bladder, Medtronic, Urology

Of those, 4.5 million are candidates for an advanced therapy, yet only 5% receive treatment3.

Key Points: 
  • Of those, 4.5 million are candidates for an advanced therapy, yet only 5% receive treatment3.
  • Implantable TNM aims to expand access to therapies for incontinence for more physicians and their patients.\nFor 25 years, Medtronic has pioneered sacral neuromodulation (SNM) therapy delivered by its implantable primary cell InterStim systems.
  • World Population Prospects: The 2010 Revision, CD-ROM Edition.\n3Leede Research, "Views on OAB: A Study for the National Association of Continence."
  • December 16, 2015.\n4Kobashi K, Nitti V, Margolis E et al.A prospective study to evaluate efficacy using the NURO percutaneous neuromodulation system in drug naive patients with overactive bladder syndrome.Urology.

Urovant Sciences Announces U.S. Commercial Launch of GEMTESA® (vibegron) 75 mg Tablets for Patients with Overactive Bladder

Retrieved on: 
Monday, April 12, 2021
Biotechnology, Pharmaceutical, Health, Anatomy, Urinary bladder disorders, Branches of biology, Medical specialties, Urinary system, Organs, Pelvis, Urinary bladder, Overactive bladder, Detrusor muscle, Bladder outlet obstruction, OAB

\xe2\x80\x9cThe launch of GEMTESA is a significant milestone for Urovant, as we are bringing our first product to market.

Key Points: 
  • \xe2\x80\x9cThe launch of GEMTESA is a significant milestone for Urovant, as we are bringing our first product to market.
  • GEMTESA is designed to reduce the bothersome symptoms of OAB by relaxing the detrusor bladder muscle so that the bladder can hold more urine.
  • GEMTESA may increase your chances of not being able to empty your bladder, especially if you have bladder outlet obstruction or take other medicines for treatment of overactive bladder.
  • Sumitovant is the majority shareholder of Myovant Sciences and wholly owns Urovant Sciences, Enzyvant Therapeutics, Spirovant Sciences, and Altavant Sciences.

FDA Approves New Indication for Drug to Treat Neurogenic Detrusor Overactivity in Pediatric Patients

Retrieved on: 
Thursday, March 25, 2021
Astellas Pharma, Ndo, Mirabegron, Urinary bladder disorders

"Mirabegron, the active ingredient in Myrbetriq and Myrbetriq Granules, works by a different mechanism of action from the currently approved treatments, providing a new treatment option for these young patients.

Key Points: 
  • "Mirabegron, the active ingredient in Myrbetriq and Myrbetriq Granules, works by a different mechanism of action from the currently approved treatments, providing a new treatment option for these young patients.
  • We remain committed to facilitating the development and approval of safe and effective therapies for pediatric NDO patients."
  • With NDO, there is overactivity of the bladder wall muscle, which normally relaxes to allow storage of urine.
  • The efficacy of Myrbetriq and Myrbetriq Granules for the pediatric NDO indication was established in a study of 86 patients ages 3 to 17 years old.

Global Overactive Bladder Treatment Market Trends, Growth Opportunities and Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 5, 2021
Health, Pharmaceutical, Urinary bladder disorders, Branches of biology, Overactive bladder, Urinary bladder

The "Overactive Bladder Treatment Market Research and Outlook, 2020 - Trends, Growth Opportunities and Forecasts to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Overactive Bladder Treatment Market Research and Outlook, 2020 - Trends, Growth Opportunities and Forecasts to 2028" report has been added to ResearchAndMarkets.com's offering.
  • It is a focused study on the Overactive Bladder Treatment market space including global and regional eight-year forecasts for revenues as well as detailed snapshots of country-wide Overactive Bladder Treatment market revenues.
  • The Overactive Bladder Treatment market report presents key trends and dynamics making an impact on the Overactive Bladder Treatment companies across the Americas, Europe, Asia Pacific, and Other markets and provides innovative approaches to stay ahead of the competition in the opportunity-rich Overactive Bladder Treatment market.
  • The report forecasts global and regional Overactive Bladder Treatment market size at granular levels for diverse types, applications, end-use segments, technologies, and niche market opportunities.

ImmunityBio Announces ASCO Genitourinary Cancer Symposium Presentation of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 71% Complete Response Rate

Retrieved on: 
Tuesday, February 16, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Infectious causes of cancer, Bladder cancer, Aging-associated diseases, Clinical medicine, Cancer, Medical specialties, Urinary bladder disorders, Histopathology, Carcinoma, BCG vaccine, Hexyl aminolevulinate hydrochloride

Patients with BCG unresponsive CIS disease face surgical removal of the bladder, a procedure fraught with high morbidity and mortality.

Key Points: 
  • Patients with BCG unresponsive CIS disease face surgical removal of the bladder, a procedure fraught with high morbidity and mortality.
  • Bladder cancer has a high incidence worldwide; it caused 212,536 deaths and an estimated 573,278 new cases were diagnosed in 20201.
  • Approximately 75-85% of all newly diagnosed cases of bladder cancer are non-muscle invasive bladder cancer (NMIBC)3.
  • The primary endpoint for Cohort A of this Phase 2/3 study is incidence of complete response (CR) of CIS at any time.

BOTOX® (onabotulinumtoxinA) Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition

Retrieved on: 
Wednesday, February 10, 2021
Anatomy, Medical specialties, Branches of biology, Urinary bladder disorders, Urinary system, Overactive bladder, Botulinum toxin, Urinary bladder, Detrusor muscle, Hyperhidrosis, Urology, Hyperkinesia

When caring for pediatric patients with neurogenic detrusor overactivity, we strive to reduce bladder pressure and increase the bladder's capacity.

Key Points: 
  • When caring for pediatric patients with neurogenic detrusor overactivity, we strive to reduce bladder pressure and increase the bladder's capacity.
  • Today, BOTOX is FDA-approved for 12 therapeutic indications, including Chronic Migraine, overactive bladder, leakage of urine (incontinence) due to overactive bladder caused by a neurologic condition in adults, cervical dystonia, spasticity, severe underarm sweating (axillary hyperhidrosis), and pediatric detrusor overactivity associated with a neurologic condition.
  • Your doctor may monitor you for breathing problems during treatment with BOTOX for spasticity or for detrusor overactivity associated with a neurologic condition.
  • Autonomic dysreflexia associated with intradetrusor injections of BOTOX could occur in patients treated for detrusor overactivity associated with a neurologic condition and may require prompt medical therapy.